References

  1. Collins AJ et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001; 12: 2465-2473. PubMed | Google Scholar

  2. Levin A. Prevalence of cardiovascular damage in early renal disease. Nephrol Dial Transplant. 2001;16[Suppl 2]: 7-11. PubMed | Google Scholar

  3. Weiner DE et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality:a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15(5): 1307-1315. PubMed | Google Scholar

  4. Panchapakesan U, Siska S, Pollock C. Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator).International Journal of Nanomedicine. 2007;2(1) :33-38. PubMed | Google Scholar

  5. Barrett BJ et al. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure: Canadian Society of Nephrology. J Am Soc Nephrol. 1999; 10[Suppl 13]: S292-S296. PubMed | Google Scholar

  6. Locatelli F et al. European Best Practice Guidelines Working Group: Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19[Suppl 2]: ii1-ii47. PubMed | Google Scholar

  7. Pollock C, McMahon L. Biochemical and hematological targets guidelines Haemoglobin. Nephrology. 2005;10 [Suppl 4]: S108-S115. PubMed | Google Scholar

  8. US Renal Data System. USRDS 2005 Annual Data Report, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Annual
    Data Report. 2005; volume 1. Google Scholar

  9. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006 ; 47[Suppl 3]: S11-S145. PubMed | Google Scholar

  10. Locatelli F et al. European Best Practice Guidelines Working Group: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19[Suppl 2]: ii1-ii47. PubMed | Google Scholar

  11. De Cock E,Van Bellingham L, Standaert B. Assessing provider time for anemia management of dialysis patients using time & motion methods: a multi-centre observational study in Europe. Value Health. 2002; 5(6): 581. PubMed | Google Scholar

  12. Macdougall IC et al. CERA (continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4(6):436-440. PubMed | Google Scholar

  13. Marian Klinger et al. Efficacy of Intravenous Methoxy Polyethylene Glycol-Epoetin Beta Administered Every 2 Weeks Compared With Epoetin Administered 3 Times Weekly in Patients Treated by Hemodialysis or Peritoneal Dialysis: A Randomized Trial. American Journal of Kidney Diseases. 2007; Vol 50, No 6 (December): pp 989-1000. PubMed | Google Scholar